A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitean-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

NCT06524544 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

320

Enrollment

NIH

Sponsor class

Conditions

Locally Advanced Urothelial Carcinoma
Metastatic Urothelial Carcinoma
Unresectable Urothelial Carcinoma

Interventions

PROCEDURE: Biospecimen Collection
DRUG: Carboplatin
DRUG: Cisplatin
PROCEDURE: Computed Tomography
DRUG: Docetaxel
DRUG: Gemcitabine
PROCEDURE: Magnetic Resonance Imaging
DRUG: Paclitaxel
BIOLOGICAL: Pembrolizumab
OTHER: Questionnaire Administration
BIOLOGICAL: Sacituzumab Govitecan

Sponsor

National Cancer Institute (NCI)